Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise

Aims/hypothesis Exenatide, a glucagon like peptide-1 agonist, is a treatment for type 2 diabetes mellitus that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. By contrast, during aerobic exercise, the serum insulin concentration normally falls, with a rise in plas...

Full description

Saved in:
Bibliographic Details
Published in:Diabetologia 2010, Vol.53 (1), p.139-143
Main Authors: Khoo, E. Y. H, Wallis, J, Tsintzas, K, Macdonald, I. A, Mansell, P
Format: Article
Language:English
Subjects:
Adult
Aerobics
Bicycling - physiology
Biological and medical sciences
Blood Glucose - drug effects
Blood Glucose - metabolism
Catecholamines
Catecholamines - blood
Diabetes
Diabetes Mellitus, Type 2 - drug therapy
Diabetes. Impaired glucose tolerance
Endocrine pancreas. Apud cells (diseases)
Endocrinology
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Exercise
Exercise - physiology
Glucagon
Glucagon - blood
Glucose
Hormones
Human Physiology
Humans
Hydrocortisone - blood
Hypoglycemia
Hypoglycemic Agents - pharmacology
Insulin
Insulin - blood
Internal Medicine
Lactates - blood
Male
Medical sciences
Medicine
Medicine & Public Health
Metabolic Diseases
Oxygen Consumption - drug effects
Peptides
Peptides - blood
Peptides - pharmacology
Physical fitness
Plasma
Reference Values
Short Communication
Statistical analysis
Venoms - blood
Venoms - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims/hypothesis Exenatide, a glucagon like peptide-1 agonist, is a treatment for type 2 diabetes mellitus that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. By contrast, during aerobic exercise, the serum insulin concentration normally falls, with a rise in plasma glucagon. We therefore assessed whether exenatide might predispose to hypoglycaemia during exercise. Methods We studied eight non-diabetic men, who were 35.3 ± 6.3 years of age with BMI of 24.7 ± 1.7 kg/m² (mean ± SD), using a randomised, crossover, double-blind design investigation. After an overnight fast, participants received 5 μg of subcutaneous exenatide or placebo and rested for 105 min before cycling at 60% of their maximal oxygen uptake ( [graphic removed] ) for 75 min and then recovering for a further 60 min. Results The insulin/glucagon molar ratio rose with exenatide at rest (p 
ISSN:0012-186X
1432-0428
DOI:10.1007/s00125-009-1579-1